The United States Food and Drug Administration (FDA) has received a request for Emergency Use Authorisation from NeuroRx Inc, a clinical stage, small molecule pharmaceutical company, for its RLF-100™ aviptadil, it was reported on Wednesday.
RLF-100 aviptadil is intended for patients with Critical COVID-19 and Respiratory Failure who are receiving intensive care and who have exhausted all approved treatments. The product is being developed by NeuroRx as part of a global collaboration with Relief Therapeutics Holdings, SA (SIX:RLF;OTCQB:RLFTF).
The company has submitted the application based on a case-control study that compared patients who were treated with RLF-100 (n=21) to those receiving maximal standard of care treatment (n=30) in the same ICU by the same medical staff. Patients treated with the product indicated a threefold advantage in survival, recovery from respiratory failure, and other parameters indicative of meaningful clinical improvement.
The company has submitted the results to a peer-reviewed journal.
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
FDA accepts rusfertide NDA and grants priority review for polycythemia vera